Ryan Cassaday, MD

Ryan Cassaday, MD

Assistant Member
Clinical Research Division

Education:

University of Washington/Fred Hutch, 2013, Hematology/Oncology Fellowship
University of Wisconsin Hospital & Clinics, 2010, Internal Medicine Residency
University of Wisconsin School of Medicine & Public Health, 2007, MD

Research Focus:

  • Developing novel therapies and risk-stratification methods for adults with acute lymphoblastic leukemia
  • Radioimmunotherapy-based conditioning regimens for hematopoietic cell transplantation in adults with high-risk lymphoma

Clinical Expertise:

  • Acute lymphoblastic leukemia
  • Aggressive non-Hodgkin lymphoma
  • Hodgkin lymphoma

Current Studies:

UW Protocol 12037: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)


CC Protocol 9111: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)


FHCRC Protocol 2361: A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies


FHCRC Protocol 2398: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma


FHCRC Protocol 2728: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies



Additional Links & Information

Related Labs & Projects

View all labs & projects >
Ryan Cassaday, MD

Contact Information

Phone
(206) 288-1202
Fax
(206) 288-1130
Email
Additional contact

Mail Stop: G6075